A California jury delivered another blow to Johnson & Johnson on Friday, ordering the healthcare giant to pay 40 million dollars to two women who claimed decades of using its talc-based baby powder led to their ovarian cancer diagnoses. The Los Angeles Superior Court verdict splits into 18 million dollars for Monica Kent and 22 million dollars for Deborah Schultz and her husband, all tagged as compensatory damages covering medical bills, suffering, and lost companionship. This marks the second massive hit in recent weeks from LA juries probing J&J’s handling of talc safety warnings.
Kent, a California resident, got her diagnosis in 2014 after roughly 40 years of post-bath powder use, while Schultz faced hers later with similar long-term habits. Both endured heavy surgeries and chemo rounds, central to trial evidence. Their lawyers hammered J&J for knowing asbestos risks since the 1960s yet burying data instead of alerting users or regulators, letting marketing roll on unchecked.
J&J’s worldwide litigation VP Erik Haas fired back fast, calling the outcome “aberrant” and vowing an immediate appeal to flip it. The company insists no solid science links cosmetic talc to ovarian cancer, pointing to U.S. health agencies’ stances and lack of proof on particle migration to ovaries. Trial defense argued only plaintiffs’ experts pushed the causal tie, urging jurors to stick to established facts.
Plaintiffs’ Case Centers on Hidden Risks:
Lawyers for Kent and Schultz leaned hard on internal J&J files showing early awareness of potential asbestos in talc mines feeding the powder supply. They claimed microscopic fibers traveled from genital use to ovaries, sparking inflammation and cancer over time. Closing arguments spotlighted how the firm allegedly prioritized sales over safety, reformulating only after lawsuits piled up.
Jurors took about a day to rule J&J liable for failing to warn, a pattern in recent California cases. Compensatory awards focus on direct harms without punitive extras this round, but the split—higher for Schultz’s family—nods to her spouse’s loss claims. No quick payout looms as appeals drag on, typical in this marathon of courtroom fights.
The women’s stories hit home: everyday routines with a trusted product turning into life battles. Their team framed it as corporate neglect, contrasting J&J’s public “safe as can be” line with private worries documented over decades.
J&J Defense and Appeal Strategy:
At trial, J&J attorney Allison Brown stressed regulatory clearances and testing regimes backing talc’s innocence. She challenged migration theories as unproven, noting agencies like FDA and CDC never flagged ovarian links. Brown painted plaintiffs’ science as cherry-picked, meant to sway rather than inform.
Company statements post-verdict doubled down: products met all standards, with global discontinuation of talc versions in 2020 driven by consumer shifts, not admissions. Haas positioned this loss as outlier amid wins elsewhere, betting appeals courts will dissect jury findings under stricter lenses. J&J eyes overturns based on prior reductions in similar verdicts. This stance holds firm despite mounting losses. Critics say it ignores juror trends in plaintiff-friendly venues like LA, where emotions run high on personal tragedies tied to household names.
The Growing Cost of the Talc Issue to J&J:
The 40 million dollar order comes after the family of a deceased lady received a 966 million dollar mesothelioma verdict in the same courthouse a few weeks ago due to lifetime exposure to powder. A docket of over 60,000 claims worldwide alleging talc cancers is under pressure due to a record-breaking award of hundreds of millions in compensation and punishment.
In 2020, J&J stopped selling talc in the United States and Canada and switched to cornstarch worldwide, but disputes still exist. Two unsuccessful bankruptcy attempts to ringfence obligations forced piecemeal trials and negotiations. Successes and failures coexist: some verdicts were overturned on appeal, while others were sustained, leaving billions set aside to fend against countless claims. Plaintiffs’ bar cheers these wins as vindication, fueling recruitment for fresh suits. J&J counters with studies and expert consensus, but juror skepticism grows amid leaked memos. Settlement overtures hover around multi-billion funds, yet gaps persist on valuing future risks.
Road Ahead in Litigation Marathon:
California courts are willing to reconsider jury instructions or the weight of the evidence, so appeals might take years. Cuts have been made by J&J in the past, such as Missouri’s 4.7 billion to 2 billion, but LA’s run puts that luck to the test. More extensive investigations are also imminent, ranging from state AG lawsuits to congressional hearings which correspond to customer harms.
For Kent and Schultz, validation comes bittersweet amid health fights. Their case spotlights enduring debates: does talc science hold firm, or do hidden contaminants tip scales? As appeals grind, it reshapes trust in everyday products and corporate accountability probes. The talc wars show no endgame soon, with verdicts piling costs and scrutiny. J&J digs in for reversals while claimants push for reckoning, turning powder aisle icons into legal lightning rods.
